The objective was to study the relationship between the levels of interleukin-1 receptor antagonist (IL-1Ra) and disease activity and the acute-phase response in SLE patients with and without renal involvement. Twenty SLE patients who had distinct active clinical manifestations (eight glomerulonephritis, four systemic vasculitis without kidney involvement, nine skin rash, 12 arthritis, ®ve serositis, four neuropsychiatric manifestations, three thrombocytopenia, one myositis and one haemolytic anaemia) were studied during a period of 8±12 months. Serum and plasma samples were taken at intervals of 6 weeks± 4 months and tested for IL-1Ra, IL-1b, IL-6, IgG and anti-dsDNA, C1q, C3, C4 and C-reactive protein (CRP). IL-1Ra serum concentrations were increased in most SLE patients with active disease when compared to normal blood donors. However, at the time of¯are, signi®cantly higher levels of IL-1Ra were observed in patients with extra-renal disease as compared to other patients (median [range]: 363 [202±3041] and 4847 [268±27 180] pg/ml for patients with and without renal involvement, respectively). This dierence was not due to proteinuria. IL-1Ra levels did not correlate with SLEDAI score durinḡ ares, but they were elevated during¯ares in patients with extra-renal manifestations. When disease activity was at its highest, IL-1Ra concentrations correlated with IL-1b (r = 0.76; P<0.001), IL-6 (r = 0.60; P<0.01) and CRP (r = 0.61; P<0.01), but not with C1q, C3, C4 and anti-dsDNA levels. The study showed that the pattern of in¯ammatory cytokines in active SLE varies in a manner that is dependent on which organs are involved. A relative absence of IL-1Ra response appears to be a feature characteristic of kidney involvement. IL-1Ra elevation clearly correlates with¯ares involving other organs.
CYTOKINES transmit information between cells and are particularly important as mediators in in¯amma-tory diseases. Under physiological conditions, proin¯ammatory and anti-in¯ammatory cytokines are controlled by inbuilt mechanisms of defence [1] . Several such mechanisms are known and include receptor antagonists, soluble cytokine receptors, inhibitory actions of dierent cytokines, and autoantibodies against cytokines. Interleukin-1 (IL-1) plays a central role in in¯ammatory processes, and its biological activities are regulated by a naturally occurring speci®c receptor antagonist (IL-1Ra) which was originally found in biological¯uids of patients with high fever and in¯ammatory diseases [2±4] . IL-1Ra, structurally related to IL-1, is secreted by monocytes/ macrophages and neutrophils, and binds to IL-1 receptors competitively without inducing any biological response [5] . IgG-containing immune complexes stimulate the production of IL-1Ra by monocytes [6] , and various cytokines (IL-4, IL-10, IL-13) enhance IL-1Ra production but inhibit IL-1 production [7] . An IL-1Ra gene polymorphism has been described and been related to disease severity, but not to disease susceptibility in systemic lupus erythematosus (SLE) [8] .
Although in¯ammation is evidently important in the pathogenesis of SLE, the response of acute-phase proteins such as C-reactive protein (CRP) is weak, especially in patients with mainly kidney and skin involvement [9] . IL-6 is know to be the main CRP inducer, but IL-1 has also been shown to be involved in this process [10] . A recent cross-sectional study showed overall elevated IL-1Ra levels in SLE, but did not explore clinical correlates or include IL-1b determinations [11] . We now report on these variables in a longitudinal study in which blood specimens were collected over 8±12 month periods surrounding¯ares of the disease.
PATIENTS AND METHODS

Patients and serum samples
SLE patients taking part in a prospective control programme at the Department of Rheumatology, Lund University Hospital were studied [12, 13] . We studied 20 consecutive patients, 1 male and 19 female, aged 25±74 yr (mean 41) who showed distinct active clinical manifestations, de®ned as a SLEDAI score of two or more, during a period of 8±12 months. The median SLEDAI score was 12 (2±5). The index was modi®ed by the exclusion of laboratory items (complement and DNA binding) to allow comparison of clinical disease activity with laboratory data [14] . All patients had a multisystemic disease and all of them ful®lled four or more of the 1982 classi®cation criteria for SLE [15] . A summary of pertinent clinical ®ndings is given in Table I . Eight patients had active kidney involvement with proteinuria (0.5 g/24 h), haematuria and/or cellular casts by urinalysis. One of these patients refused kidney biopsy. In all the others a diuse proliferative glomerulonephritis (WHO class IV) was documented. Four patients had systemic vasculitis without kidney involvement, nine skin rash, 12 arthritis, ®ve serositis, four neuropsychiatric manifestations, three thrombocytopenia, one myositis and one patient haemolytic anaemia during¯are. During the observation period, all patients with kidney involvement were treated with cytostatic drugs (pulse cyclophosphamide four, chlorambucil one, azathioprine three). Among the patients with extra-renal¯ares, four were treated with azathioprine, three with antimalarial drugs and two with cyclosporin. The median daily dose of glucocorticoids during 2 weeks prior to blood sampling at¯are is given in Table I . Of all patients, only one with kidney involvement had been treated with cytostatic drugs, azathioprine at low dosage, prior to¯are. At the time of¯are, glucocorticoids were instituted in all patients, but blood sampling was performed before the start of treatment or increase of dosage (Table I) .
From each patient, ®ve serum and plasma samples were obtained at intervals of 6 weeks±4 months. In 14 patients, 1±4 blood samples were obtained prior to¯are. Six of the patients were admitted with high disease activity and blood samples obtained during and after the¯are period were analysed. The blood samples were obtained in standardized manner in the morning before the ®rst meal. After venepuncture, clotting was allowed to proceed for 1 h at room temperature, followed by 1 h at 48C. After separation by centrifugation, serum and plasma samples were frozen in small aliquots at À808C.
Enzyme-linked immunosorbent assay (ELISA) for IL-1Ra, IL-6 and IL-1b IL-1Ra was measured by quantitative`sandwich' immunoassay provided by R&D Systems, Minneapolis, MN, USA. In 32 healthy individuals, IL-1Ra concentrations were median (range) 433 (256±800) pg/ml. IL-6 was measured using a quantitative immunoassay provided by Medgenix SA, Fleurus, Belgium. The normal value is <15 pg/ml. IL-1b was measured by a sensitive ELISA with detection limit of 0.1 pg/ml, Quantikine HS human IL-1b, R&D Systems, USA. The range in 10 normal sera was 0.425±2.829 (median 1.331) pg/ml. IL-1b was determined on only two occasions in each patient: at peak of¯are and at remission.
Other assays
IgG isotype antibodies to dsDNA were determined by plasmid ELISA essentially as described by Emlen et al. [16] . Concentrations of C1q, C4 and C3 were determined by electroimmunoassay [17] .
CRP was measured by electroimmunoassay. The urine concentration of albumin was measured by immunoturbidimetry and the urinary excretion of albumin was expressed as fractional albumin creatinine clearance [18] . The normal level is <0.01-.
Statistics
Dierences between groups were calculated using Mann±Whitney's U-test. Correlations were calculated with the Spearman rank correlation coecient. Owing to multiple testing, only P values <0.01 were considered signi®cant. Figure 1a shows individual SLEDAI scores in patients with renal or extra-renal activity. In Fig. 1b , the IL-1Ra values are given, demonstrating that IL1Ra serum concentrations are very variable in SLE (median 369, range 268±27 180 pg/ml). In normal blood donors, IL-1Ra levels were median 433, range 256±800. Furthermore, it is clear that patients with extra-renal¯ares usually had very marked IL-1Ra responses (median 4847 [268±27 180] pg/ml), whereas the renal¯ares were associated with no or only modest increases (363 [202±3041] pg/ml). The dierence was signi®cant (P<0.01). The highest IL-1Ra concentrations were found in a female patient with myositis, rash and arthritis (27 180 pg/ml), and in another with haemolytic anaemia and arthritis (16 152 pg/ml). Two patients with renal involvement had initially high serum levels of IL-1Ra. One of them, a 55-yr-old woman, presented with minor cerebral infarction, skin rash and discoid lesions, and the other, a 26-yr-old woman, had skin rash and polyarthritis in addition to the kidney manifestations.
RESULTS
In Table II , data are given on kidney function, proteinuria and IL-1Ra levels. No correlation was FIG. 1.Ð(a±e) Serial follow-up of 20 SLE patients. The time point for maximal disease activity or the time point for the start of cytostatic treatment is denoted as time 0. Disease activity was estimated by a SLEDAI score, IL-1Ra was given as pg/ml, IL-6 as pg/ml, CRP as mg/ml and anti-dsDNA in arbitrary units/ml.
found between the amount of proteinuria, expressed as fractional albumin creatinine clearance, and serum levels of IL-1Ra (r = À 0.08; P = 0.84). IL-1Ra levels were not correlated with glomerular ®ltration rate or S-creatinine. All patients without kidney involvement had normal S-creatinine and no proteinuria.
Five of the eight patients with kidney involvement were treated with prednisolone prior to¯are compared with ®ve of the other 12 patients who were taking this drug. No signi®cant correlation was found between prednisolone dosage and IL-1Ra serum levels (r = À 0.35; P = 0.12). Figure 1b shows that the IL-1Ra serum concentrations were higher at the time of¯are than during inactive disease, but no overall correlation between IL-1Ra levels and SLEDAI scores was found durinḡ are. Table III shows the levels of IL-1b, IL-6 and IL-1Ra at the peak of disease activity and at remission in the 20 patients. IL-1b levels were slightly increased in as few as three patients. The highest concentration, 4.43 pg/ml, was found in the patient with arthritis and haemolytic anaemia who had high IL-1Ra serum concentration (16 152 pg/ml). IL-1Ra correlated with IL-1b levels (r = 0.76; P<0.001). A close correlation was also found between IL-1b and IL-6 concentrations (r = 0.87; P<0.001). In patients with extra-renal manifestations, increased levels of IL-6 ( Fig. 1c) and CRP (Fig. 1d) were common. The serum concentrations of IL-6 were slightly increased in four patients with glomerulonephritis at the peak of disease activity. All four patients had concomitant extra-renal manifestations and CRP was increased in two of them ( Fig. 1c and d) . One patient with extrarenal systemic vasculitis developed venous thrombosis 4 months after the peak of her¯are, accounting for the high CRP value at that time (Fig. 1d) . No evidence of infection was found in the patient. SLEDAI did not correlate with IL-6 or CRP. Peak levels during¯are-ups correlated for IL-1Ra and CRP (r = 0.61; P<0.01).
Simultaneously, correlations were observed between IL-6 and IL-1Ra (r = 0.60; P<0.01) and Normal (95% con®dence limits): Cr-EDTA clearance >80 ml/min; S-creatinine 60±115 for men, 50±100 for women; FACC <0.01-. The range of IL-1Ra in 32 healthy individuals was 256±800 pg/ml. between IL-6 and CRP (r = 0.72; P<0.001). No correlation was found between IL-1Ra and total white cell count, C1q, C3, C4 or anti-dsDNA antibody levels. IL-1Ra levels were more closely related tō are-ups in time than anti-dsDNA (Fig. 1b and e) . In patients with kidney involvement, the anti-dsDNA levels tended to be higher than during the post-¯are period (Fig. 1e) .
SLEDAI showed an inverse relationship with complement components C1q (r = À 0.58; P<0.01), C4 (r = À 0.40; not signi®cant) and C3 (r = À 0.50; P<0.05). As expected, hypocomplementaemia was most pronounced in patients with kidney involvement.
DISCUSSION
We demonstrated in this paper that the concentrations of circulating IL-1Ra vary considerably with the disease course in SLE and with dierent types of SLE manifestations. Recently, Suzuki et al. [11] reported in a cross-sectional study that levels of IL-1Ra are commonly increased in active SLE. We found, however, that very high concentrations of IL-1Ra were restricted to patients with extra-renal disease and that the serum levels in patients with kidney involvement were low or only moderately increased. Notably, one of the patients with very high IL-1Ra concentrations had myositis which is consistent with a previous report of IL-1Ra in polymyositis/dermatomyositis [19, 20] .
The very high concentrations of IL-1Ra in patients with active extra-renal SLE indicate that mononuclear cells are activated by adherent IgG, immune complexes or other stimulators such as IL-4, IL-10 and IL-13. In SLE patients with kidney disease, very high concentrations of immune complexes and pronounced complement activation can be found regularly [12] . This observation, seen in the context of the present ®ndings regarding IL-1Ra, suggests that cytokine-enhanced IL-1Ra production is more eective in extra-renal SLE. The low IL-1b and IL-6 concentrations found in patients with active kidney involvement, and the moderately high IL-1b and IL-6 levels in patients with extra-renal¯ares, are probably in accordance with this notion.
It could be argued that the relatively low levels of IL-1Ra associated with renal¯ares are a consequence of urinary loss. However, this seems highly unlikely to us. Increased IL-1Ra levels have previously been found in patients with reduced kidney function [21] . In our patients, no correlation was found between IL-1Ra levels and proteinuria, renal function as measured by S-creatinine and glomerular ®ltration (Cr-EDTA clearance) or fractional albumin creatinine clearance, a sensitive and accurate method to measure renal protein excretion [18] .
The proportion of patients with kidney involvement who were treated with prednisolone during the pre-¯are period was slightly higher, but no correlation was found between the pre-¯are prednisolone dose and IL-1Ra concentrations. However, it cannot be ruled out that the glucocorticoid treatment may have contributed to lower IL-1Ra production in the patients with glomerulonephritis, but this can hardly be the main explanation.
Suzuki et al. [11] recently reported that monocytes from SLE patients, as compared to normal monocytes, produced increased amounts of IL-1Ra in vitro. This was in contrast with Schur et al. [22] who found low production of IL-1 inhibitor by SLE monocytes in a similar test system. In the light of the present investigation, the discrepant ®ndings could at least in part be explained by clinical dierences between studied patient groups. Moreover, defective production of IL-1Ra by polymorphonuclear neutrophils, which are a main source of IL-1Ra, has recently been shown in patients with active SLE [23] .
The SLEDAI index is a weighted activity index, giving the highest scores to patients with kidney and central nervous system involvement [14] . A weak inverse relationship between SLEDAI and IL-1Ra (r = À 0.35) was found in the studied group of patients, which is explained by the weighting of the SLEDAI index. The inverse correlation between SLEDAI and complement components, especially C1q, is in accordance with activation and consumption of classical pathway components in active severe SLE [24] . The levels of high-avidity anti-dsDNA antibodies showed no consistent pattern in relation to the disease course with the exception that higher concentrations were seen prior to¯are than during the postare period in patients with kidney involvement. Discrepancies in relation to¯are and the predictive value in the course of SLE of high-avidity antidsDNA antibodies were recently reviewed by Esdaile et al. [25] .
By polymerase chain reaction typing, a polymorphism has been described for the IL-1Ra gene on chromosome 2 close to the genes encoding IL-1a and IL-1b [26] . Interestingly, the IL-1RN*2 allele is more common in SLE, and has been associated with extensive disease with skin involvement and also low levels of circulating IL-1Ra [8] . All our patients with renal involvement had skin disease and ful®lled a high number of ACR criteria consistent with those observations. It is possible that polymorphisms of the IL-1Ra gene could be related to dierences in the production of IL-1Ra in active disease, explaining the low IL-1Ra concentrations in patients with lupus nephritis. Thus, while MHC class II and III genes appear to be important for susceptibility to SLE, the IL-1RN gene polymorphism may in¯uence the severity and outcome of the disease.
In this study, we found a correlation between IL-1Ra and IL-6. Furthermore, we found a signi®c-ant correlation between CRP and IL-1Ra, and also between IL-6 and CRP. The latter observation is in contrast with that made previously by Gabay et al. [27] . However, this study was cross-sectional and patients were enrolled at dierent stages of disease activity, and not distinguished according to their renal and extra-renal manifestations. Furthermore, an IL-6 bioassay was used. Therefore, both methodological dierences and patient selection could contribute to the discrepant ®ndings. Our data support previous reports in that SLE patients with extra-renal manifestations such as serositis and vasculitis do have an adequate acute-phase response in terms of CRP levels, while patients with severe SLE manifestations such as glomerulonephritis have a low acutephase response [12] . IL-1Ra thus has features of an acute-phase protein with a sensitivity equalling that of CRP (Fig. 1b and d) .
Low serum concentration of IL-1Ra during¯are appears to indicate extensive disease and, together with low levels of circulating C1q [12, 28] , to be a marker of kidney involvement in active lupus. Further serial studies, amongst others concerning the expression of IL-1Ra mRNA in circulating cells and in tissues such as lymph nodes and kidneys, are necessary to elucidate the role of IL-1Ra in the pathogenesis of SLE.
